KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

KBC Group NV grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 2,275.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 61,010 shares of the biopharmaceutical company's stock after purchasing an additional 58,442 shares during the quarter. KBC Group NV owned about 0.07% of Ultragenyx Pharmaceutical worth $2,567,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. True Wealth Design LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at about $56,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth about $83,000. Nomura Asset Management Co. Ltd. acquired a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth about $93,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $107,000. 97.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 22nd. Wells Fargo & Company raised their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a report on Friday, December 20th. Wedbush reaffirmed a "neutral" rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. JPMorgan Chase & Co. dropped their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, November 21st. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $92.43.

Ultragenyx Pharmaceutical Stock Up 2.7 %

Shares of NASDAQ RARE traded up $1.19 during trading hours on Wednesday, hitting $45.37. The company had a trading volume of 554,529 shares, compared to its average volume of 956,245. The stock has a market capitalization of $4.19 billion, a P/E ratio of -7.01 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm's 50 day moving average is $44.09 and its 200-day moving average is $49.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. During the same quarter last year, the firm posted ($2.23) EPS. The company's quarterly revenue was up 42.3% on a year-over-year basis. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.13 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Emil D. Kakkis sold 11,727 shares of the firm's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.